David J. Schlanger Sells 5,826 Shares of Progyny, Inc. (NASDAQ:PGNY) Stock (2024)

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) Chairman David J. Schlanger sold 5,826 shares of Progyny stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $37.74, for a total transaction of $219,873.24. Following the completion of the sale, the chairman now owns 86,312 shares of the company's stock, valued at approximately $3,257,414.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Progyny Trading Down 0.6 %

3 Best Stocks to Buy That You’ve Probably Never Heard Of

NASDAQ PGNY opened at $37.00 on Tuesday. The stock's 50-day moving average price is $37.95 and its two-hundred day moving average price is $35.58. The company has a market cap of $3.57 billion, a PE ratio of 59.68, a PEG ratio of 1.54 and a beta of 1.48. Progyny, Inc. has a 1 year low of $29.44 and a 1 year high of $44.95.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. The firm had revenue of $269.94 million for the quarter, compared to the consensus estimate of $274.08 million. Progyny had a return on equity of 12.64% and a net margin of 5.70%. The business's revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.03 EPS. Research analysts forecast that Progyny, Inc. will post 0.7 EPS for the current fiscal year.

Institutional Trading of Progyny

[BUY ALERT] Our #1 A.I. Stock for March

From Behind the Markets | Ad

It's the one AI stock nobody is talking about.Cathy Wood just bought 11 million shares of it.

Get the name of the stock here - before it takes off >>>

Several institutional investors and hedge funds have recently bought and sold shares of PGNY. RiverPark Advisors LLC grew its stake in Progyny by 54.0% during the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company's stock valued at $40,000 after acquiring an additional 374 shares in the last quarter. Rockefeller Capital Management L.P. grew its stake in Progyny by 3,119.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,674 shares of the company's stock valued at $50,000 after acquiring an additional 1,622 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Progyny during the 3rd quarter valued at about $53,000. Lazard Asset Management LLC grew its stake in Progyny by 45.2% during the 4th quarter. Lazard Asset Management LLC now owns 1,763 shares of the company's stock valued at $54,000 after acquiring an additional 549 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new position in Progyny during the 3rd quarter valued at about $58,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Ratings Changes

PGNY has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $48.00 price target on shares of Progyny in a research note on Wednesday, February 28th. KeyCorp decreased their price objective on shares of Progyny from $45.00 to $43.00 and set an "overweight" rating for the company in a report on Wednesday, February 28th. Truist Financial decreased their price objective on shares of Progyny from $47.00 to $46.00 and set a "buy" rating for the company in a report on Wednesday, February 28th. SVB Leerink began coverage on shares of Progyny in a report on Monday, February 26th. They issued an "outperform" rating and a $49.00 price objective for the company. Finally, Leerink Partnrs reissued an "outperform" rating on shares of Progyny in a report on Monday, February 26th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Progyny has an average rating of "Buy" and a consensus target price of $48.30.

Read Our Latest Report on Progyny

Progyny Company Profile

(Get Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected].

Insider Buying or Selling at Progyny?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Progyny and related companies.